Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Oslo, Norway – 26 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers,...
-
Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026. The General Meeting will be held electronically and all...
-
Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces...
-
Oslo, Norge, 9. mars 2026 – Zelluna (OSE: ZLNA) er et banebrytende selskap innen utvikling av allogene "off-the-shelf" T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide...
-
Oslo, Norway, 09 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers,...
-
Regulatorisk godkjenning muliggjør oppstart av klinisk testing og markerer overgang til klinisk faseFørste kliniske data forventes fra medio 2026 Oslo, Norge, 20 februar 2026 – Zelluna (OSE: ZLNA)...
-
Regulatory clearance enables start of clinical testing and marks transition to clinical-stage companyOn track for initial clinical data to emerge from mid-2026 Oslo, Norway, 20 February 2026 –...
-
Oslo, 12. februar 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte Natural Killer (TCR-NK) celleterapier for behandling av kreft, presenterer i dag...
-
Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today...
-
Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA ...